Search results
Results from the WOW.Com Content Network
The next two years may be a bit financially tight for CRISPR Therapeutics, which represents a risk for those who buy the stock now. As of the second quarter, it has about $484 million in cash ...
CRSP Market Cap data by YCharts. 3. Intensive competition. The success of CRISPR Therapeutics will depend on its ability to bring multiple new drugs to the market to support a more viable business ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
CRISPR Therapeutics (NASDAQ: CRSP), ... Its price in the U.S. is $2.2 million. Its total addressable market includes about 35,000 patients in the U.S. and Europe and an additional 23,000 in Saudi ...
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $118.91, moving -0.24% from the previous trading session.
On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. After all, it's been less than a year since regulators in the U.S. and E.U. approved its ...
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...